21-norvitamin D compounds

Details 21-norvitamin D compounds 21-norvitamin D compounds

1993-11-24

1995-01-24

Richter, Johann

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

552653, C07C40100

Patent

active

053843134

ABSTRACT:
21-norvitamin D.sub.3 analogs in which the methyl group normally attached to the side chain at carbon 20 has been replaced by a hydrogen atom. The compounds are characterized by a marked intestinal calcium transport activity while exhibiting much lower activity than 1.alpha.,25-dihydroxyvitamin D.sub.3 in their ability to mobilize calcium from bone. Because of their preferential calcemic activity, these compounds are useful for the treatment of diseases where bone formation is desired, such as osteodystrophy. Novel intermediates formed during the synthesis of the end products are also disclosed.

REFERENCES:
patent: 4711881 (1987-12-01), Ikekawa
"Synthetic Studies of Vitamin D Analogues. X. Synthesis and Biological Activities of 1.alpha.,25-Dihydroxy-21-norvitamin D.sub.3 ", Chem. Pharm. Bull., Kubodera et al. vol. 40, No. 3, pp. 648-651.

Affiliated with

Also associated with

Rating

21-norvitamin D compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 21-norvitamin D compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 21-norvitamin D compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1468696